Primary human hepatocytes are widely used to evaluate liver toxicity of drugs, but they are scarce and demanding to culture. Stem cell-derived hepatocytes are increasingly discussed as alternatives. To obtain a better appreciation of the molecular processes during the differentiation of induced pluripotent stem cells into hepatocytes, we employ a quantitative proteomic approach to follow the expression of 9,000 proteins, 12,000 phosphorylation sites, and 800 acetylation sites over time. The analysis reveals stage-specific markers, a major molecular switch between hepatic endoderm versus immature hepatocyte-like cells impacting, e.g., metabolism, the cell cycle, kinase activity, and the expression of drug transporters. Comparing the proteome...
Deeper understanding of liver pathophysiology would benefit from a comprehensive quantitative proteo...
A successful drug needs to display beneficial absorption, distribution, metabolism, excretion and to...
Human primary hepatocytes (pHEPs) are used as the gold standard model for drug screening and toxicit...
Primary human hepatocytes are widely used to evaluate liver toxicity of drugs, but they are scarce a...
Numerous in vitro models endeavour to mimic the characteristics of primary human hepatocytes for ap...
Numerous in vitro models endeavour to mimic the characteristics of primary human hepatocytes for app...
Failure to predict hepatotoxic drugs in preclinical testing makes it imperative to develop better li...
Experimental drugs need to be screened for safety within time constraints. Hepatotoxicity is one con...
Background & AimsHepatocyte-like cells (HLCs), differentiated from pluripotent stem cells by the use...
Background & Aims Hepatocyte-like cells (HLCs), differentiated from pluripotent stem cells by the us...
Human pluripotent stem cell-derived hepatocytes (hPSC-HEP) display many properties of mature hepatoc...
In vitro preclinical models for the assessment of drug-induced liver injury (DILI) are usually based...
Hepatocytes derived from human pluripotent stem cells (hPSC-HEP) have the potential to replace prese...
The potential to differentiate human embryonic stem cells (hESCs) in vitro to provide an unlimited s...
Deeper understanding of liver pathophysiology would benefit from a comprehensive quantitative proteo...
A successful drug needs to display beneficial absorption, distribution, metabolism, excretion and to...
Human primary hepatocytes (pHEPs) are used as the gold standard model for drug screening and toxicit...
Primary human hepatocytes are widely used to evaluate liver toxicity of drugs, but they are scarce a...
Numerous in vitro models endeavour to mimic the characteristics of primary human hepatocytes for ap...
Numerous in vitro models endeavour to mimic the characteristics of primary human hepatocytes for app...
Failure to predict hepatotoxic drugs in preclinical testing makes it imperative to develop better li...
Experimental drugs need to be screened for safety within time constraints. Hepatotoxicity is one con...
Background & AimsHepatocyte-like cells (HLCs), differentiated from pluripotent stem cells by the use...
Background & Aims Hepatocyte-like cells (HLCs), differentiated from pluripotent stem cells by the us...
Human pluripotent stem cell-derived hepatocytes (hPSC-HEP) display many properties of mature hepatoc...
In vitro preclinical models for the assessment of drug-induced liver injury (DILI) are usually based...
Hepatocytes derived from human pluripotent stem cells (hPSC-HEP) have the potential to replace prese...
The potential to differentiate human embryonic stem cells (hESCs) in vitro to provide an unlimited s...
Deeper understanding of liver pathophysiology would benefit from a comprehensive quantitative proteo...
A successful drug needs to display beneficial absorption, distribution, metabolism, excretion and to...
Human primary hepatocytes (pHEPs) are used as the gold standard model for drug screening and toxicit...